Literature DB >> 14607272

The role of the C-terminal tail in protease-activated receptor-2-mediated Ca2+ signalling, proline-rich tyrosine kinase-2 activation, and mitogen-activated protein kinase activity.

Michael J Seatter1, Robert Drummond, Toru Kanke, Scott R Macfarlane, Morley D Hollenberg, Robin Plevin.   

Abstract

C-terminal truncation mutants were made to investigate the role of the C-terminus in coupling proteinase-activated receptor-2 (PAR-2) to various signalling pathways. Membrane expression of the delta15, delta34, delta43, and delta34-43 mutants was similar; however, expression of deltatail was lost, as was agonist-mediated internalisation of deltatail, delta43, and delta34-43. Additionally, trypsin and SLIGKV-stimulated [3H]IP accumulation was abrogated in cells transiently expressing delta43 or delta34-43 truncations, but remained unaffected in cells expressing delta34 or delta15. PAR-2 agonist-stimulated intracellular Ca(2+) mobilisation and PYK-2 activity were also abolished by deltatail, delta43, and delta34-43 mutants. However, trypsin-stimulated stress-activated protein kinases (SAPKs) or extracellular signal-regulated kinase (ERK) activities were unaffected by the delta34-43 mutation, although activity was abrogated following delta43 or deltatail truncations, suggesting that Ca(2+) mobilisation, PYK-2, or receptor internalisation are not requied for activation of SAPKs or ERK. These studies identify a novel sequence within the PAR-2 C-terminus essential for InsP(3) generation and PYK-2 activity but not mitogen-activated protein kinase (MAPK) activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14607272     DOI: 10.1016/s0898-6568(03)00095-0

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  14 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 3.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

4.  Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.

Authors:  Toru Kanke; Hiroyuki Ishiwata; Mototsugu Kabeya; Masako Saka; Takeshi Doi; Yukio Hattori; Atsufumi Kawabata; Robin Plevin
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

5.  Divergent β-arrestin-dependent signaling events are dependent upon sequences within G-protein-coupled receptor C termini.

Authors:  Kasturi Pal; Maneesh Mathur; Puneet Kumar; Kathryn DeFea
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

6.  The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes.

Authors:  Scott R Macfarlane; Callum M Sloss; Pamela Cameron; Toru Kanke; Roderick C McKenzie; Robin Plevin
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

7.  Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells.

Authors:  E Ritchie; M Saka; C Mackenzie; R Drummond; C Wheeler-Jones; T Kanke; R Plevin
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

8.  Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins.

Authors:  Ping Wang; Puneet Kumar; Chang Wang; Kathryn A Defea
Journal:  Biochem J       Date:  2007-12-01       Impact factor: 3.857

Review 9.  The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders.

Authors:  Trevor Bushell
Journal:  J Physiol       Date:  2007-03-08       Impact factor: 5.182

10.  Interaction of Protease-Activated Receptor 2 with G Proteins and β-Arrestin 1 Studied by Bioluminescence Resonance Energy Transfer.

Authors:  Mohammed Akli Ayoub; Jean-Philippe Pin
Journal:  Front Endocrinol (Lausanne)       Date:  2013-12-20       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.